Clinical trials: Select Advanced Malignancies, open to volunteers
Colorectal Cancer
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
- Trial name
- NCT07722494
- Testing
- IBI363 + bevacizumab, Investigator's choice of therapy
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neuroendocrine Carcinoma
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
- Trial name
- TARLANEC (NCT06937905)
- Testing
- Standard of Care Chemotherapy, Tarlatamab
- Where
- 40 sites in France
- Volunteers
- 129 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic…
- Conditions
- Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- DUET-BTC (NCT07641036)
- Testing
- EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Advanced Solid Tumor
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations.
- Trial name
- BoB (NCT03767075)
- Testing
- Atezolizumab, Futibatinib, Amivantamab
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Locally Advanced Rectal Cancer (LARC)
Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This interventional, non-randomized, prospective trial aims to evaluate the role of endoscopic resection following neoadjuvant treatment in patients with locally advanced rectal cancer.
- Trial name
- OPAL (NCT06761287)
- Testing
- Endoscopic resection, Short interval restaging, Total mesorectal excision
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Advanced Solid Tumor, PDAC
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for…
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Trial name
- NCT06597721
- Testing
- ADCE-T02
- Where
- 14 sites in United States, Australia
- Volunteers
- 210 people
- Sponsor
- Adcendo ApS
Endometrial Cancer, Malignant Solid Tumour
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants…
- Trial name
- NCT07044336
- Testing
- Puxitatug Samrotecan, Doxorubicin, Paclitaxel
- Where
- 320 sites in United States, Argentina and 26 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Advanced Endometrial Cancer
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
- Trial name
- NCT06584032
- Testing
- fruquintinib, sintilimab, paclitaxel
- Where
- 17 sites in China
- Volunteers
- 412 people
- Sponsor
- Hutchmed
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Upper Tract Urothelial Carcinoma
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for…
- Trial name
- NCT06798246
- Testing
- Chemotherapy, Immunotherapy, ADC
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021[7]-2030[6]), including a multidisciplinary training program…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable, Chemotherapy Effect
- Trial name
- PREOPANC-4 (NCT05524090)
- Testing
- Implementation - International best-practice care
- Where
- Netherlands
- Volunteers
- 223 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)